What kind of rash can happen with Keytruda (pembrolizumab)?
Rash is a known side effect of Keytruda (pembrolizumab). It can range from mild skin irritation to more serious immune-related skin reactions, including severe blistering or widespread rash. Because Keytruda works by boosting the immune system, skin reactions can happen when the immune system attacks healthy skin as well as, less commonly, due to other causes happening at the same time.
When should a Keytruda rash be treated as urgent?
Seek urgent medical care right away (or contact your oncology team urgently) if the rash comes with any of these warning signs:
- Blistering, peeling skin, or painful sores
- Rash spreading quickly or covering a large part of the body
- Fever, feeling very ill, or new trouble breathing
- Rash with eye involvement (redness, pain, light sensitivity) or mouth/genital sores
These symptoms can point to severe immune-mediated skin conditions that need prompt treatment.
How does clinicians decide if it’s an immune-related rash from Keytruda?
Doctors usually weigh how the rash looks and how severe it is, how fast it appeared, and whether there are signs of immune involvement elsewhere. They often consider:
- Timing: symptoms starting after starting Keytruda or after a recent dose
- Severity: covering area, blistering/peeling, and pain
- System symptoms: fever, sores in mouth/eyes/genitals, or other organ symptoms
- Rule-outs: infections, allergies to other medicines, or contact dermatitis
This is why it’s important not to just self-treat without telling the prescriber.
What treatments are commonly used for Keytruda-related rash?
Treatment depends on severity and may include:
- Topical corticosteroids for mild cases
- Oral corticosteroids for moderate cases
- Stopping or holding Keytruda and using systemic therapy for more severe immune skin reactions
- Dermatology involvement and, for severe cases, hospital-level care
Your oncology team may also recommend antihistamines for itch, but the key decision is whether the immune reaction is mild enough to continue Keytruda or severe enough to pause it.
Can patients keep taking Keytruda if they develop a rash?
Sometimes yes, but not always. The usual approach is based on severity:
- Mild rash may be managed while continuing Keytruda with supportive skin care and close monitoring.
- Moderate to severe rashes often lead to holding Keytruda and starting stronger anti-inflammatory therapy.
- Severe blistering/peeling reactions typically require urgent intervention and may result in permanent discontinuation.
Only your prescriber can decide after grading the reaction.
What can patients do at home while waiting to be seen?
Practical steps that are generally safe while contacting your oncology team include:
- Take photos of the rash and note the date it started and whether it’s spreading
- Avoid new skin products, hot showers, or fragranced lotions
- Use gentle, fragrance-free moisturizers if your clinician hasn’t told you to avoid them
- Don’t start leftover steroid pills or antibiotics without guidance from your treatment team, because the right plan depends on rash severity
Other causes of rash that may look similar
Not every rash during immunotherapy is caused by Keytruda. Rashes can also come from:
- Viral or bacterial infections
- Medication allergies to other drugs (including antibiotics, anti-seizure meds, NSAIDs, or supportive cancer meds)
- Contact dermatitis from soaps, adhesives, or topical products
- Other autoimmune issues not directly tied to Keytruda
That’s another reason clinicians may involve dermatology and sometimes run tests.
If you want, tell me what your rash looks like and when it started
If you share:
- when you started Keytruda (and your most recent dose date),
- where the rash is (face, trunk, hands/feet, folds),
- whether it itches or hurts,
- any blistering/peeling, fever, mouth sores, or eye symptoms,
I can help you think through how urgent it sounds and what to ask your oncology team.